This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Pan, Y. Articles by Haines, D. S. Search for Related Content PubMed PubMed Citation Articles by Pan, Y. Articles by Haines, D. S.

The Pathway Regulating MDM2 Protein Degradation Can Be Altered in Human Leukemic Cells¹

Barry Ashbee Leukemia Research Laboratories, Hahnemann University Hospital, Philadelphia, Pennsylvania 19102

The MDM2 protein regulates the functional activity of the p53 tumor suppressor through direct physical association. Signals that control MDM2 expression are poorly understood but are likely to play an important role in the regulation of p53 activity. We show here that the half-life of MDM2 protein is shorter in proliferating than in quiescent peripheral blood mononuclear cells. We also demonstrate that MDM2 protein half-life is extended in some, but not all, p53 mutant human leukemic cell lines. In at least one of these p53 mutant lines, increased MDM2 protein stability is associated with higher amounts of MDM2 protein. Moreover, we demonstrate that MDM2 protein accumulates to a much greater extent in proteasome inhibitor-treated cells containing unstable MDM2 than in cells possessing stable MDM2. These results demonstrate that MDM2 expression is regulated by events that control the stability of the protein and suggest that the normal regulation of MDM2 turnover can be altered in tumor cell lines.

This article has been cited by other articles:

				J. Feng, R. Tamaskovic, Z. Yang, D. P. Brazil, A. Merlo, D. Hess, and B. A. Hemmings Stabilization of Mdm2 via Decreased Ubiquitination Is Mediated by Protein Kinase B/Akt-dependent Phosphorylation J. Biol. Chem., August 20, 2004; 279(34): 35510 - 35517. [Abstract] [Full Text] [PDF]

				Z. Zhang, H. Wang, G. Prasad, M. Li, D. Yu, J. A. Bonner, S. Agrawal, and R. Zhang Radiosensitization by Antisense Anti-MDM2 Mixed-Backbone Oligonucleotide in in Vitro and in Vivo Human Cancer Models Clin. Cancer Res., February 15, 2004; 10(4): 1263 - 1273. [Abstract] [Full Text] [PDF]

				H. WANG, P. OLIVER, Z. ZHANG, S. AGRAWAL, and R. ZHANG Chemosensitization and Radiosensitization of Human Cancer by Antisense Anti-MDM2 Oligonucleotides: In Vitro and in Vivo Activities and Mechanisms Ann. N.Y. Acad. Sci., December 1, 2003; 1002(1): 217 - 235. [Abstract] [Full Text] [PDF]

				J. Garriga, S. Bhattacharya, J. Calbo, R. M. Marshall, M. Truongcao, D. S. Haines, and X. Grana CDK9 Is Constitutively Expressed throughout the Cell Cycle, and Its Steady-State Expression Is Independent of SKP2 Mol. Cell. Biol., August 1, 2003; 23(15): 5165 - 5173. [Abstract] [Full Text] [PDF]

				Y. Peng, L. Chen, C. Li, W. Lu, S. Agrawal, and J. Chen Stabilization of the MDM2 Oncoprotein by Mutant p53 J. Biol. Chem., February 23, 2001; 276(9): 6874 - 6878. [Abstract] [Full Text] [PDF]